BVBirgit Vogel

Birgit Vogel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Birgit Vogel has a total of 260 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Translational Perspectives on Cardiac Diseases Disproportionately Affecting Women

    by Naja Dam Mygind, Gershim Asiki, Blanche Cupido, Lasse Gliemann, Kristina Hermann Haugaa, Ylva Hellsten, Cecilia Linde, Mette Nyegaard, Elimir Omerovic, Ambuj Roy, et al.

    Significant knowledge gaps persist on cardiovascular conditions that predominantly, disproportionately, or only affect women. Historically overshadowed by the focus on obstructive coronary artery disease, conditions such as myocardial infarction with nonobstructive coronary arteries, spontaneous coronary artery dissection, and Takotsubo cardiomyopathy have only recently gained research attention, despite substantial prevalence and impact among women. Similarly, coronary microvascular dysfunction and vasospastic angina, long dismissed as symptoms of psychological origin, are now recognized as common and underdiagnosed mechanisms of chest pain. Disparities in research also extend to heart failure with preserved ejection fraction, disproportionately affecting more women, and with comparable impacts on prognosis and quality of life, yet poorly understood compared with heart failure with reduced ejection fraction. Moreover, female hypertension is underestimated, underdiagnosed, and understudied. Furthermore, pregnancy‐related cardiovascular complications, including preeclampsia and peripartum cardiomyopathy underscore the urgent need for research into sex‐specific mechanisms and targeted preventive and therapeutic strategies, particularly in resource‐limited settings. This review consolidates knowledge on cardiovascular conditions with pronounced sex differences, focusing on translational discoveries that direct current strategies, but most of all, emphasizing the need for future research to bridge the gap between mechanistic insights and clinical application. By identifying knowledge gaps, this article provides a road map for advancing sex‐specific understanding and care in cardiovascular disease, ensuring progress in diagnosis, treatment, and prevention. Bridging the sex gap in cardiac research and care requires a multidisciplinary, globally inclusive approach. By integrating knowledge of biological, clinical, and sociocultural perspectives, we can move toward equitable and effective cardiovascular health for all.

  • Open Access

    Sex Differences in Outcomes by Revascularization Strategy in Patients With Femoropopliteal Peripheral Arterial Disease: A Substudy of the REVIVE Pooled Analysis

    by Birgit Vogel, Serdar Farhan, Florian K. Enzmann, Patrick Bjorkman, Haroon Kamran, Samantha Sartori, Yihan Feng, Klaus Linni, Maarit Venermo, Daphne van der Veen, et al.

    Background: Women have been underrepresented in peripheral artery disease revascularization trials. We aimed to analyze sex‐specific outcomes after endovascular therapy (EVT) with stent implantation versus bypass surgery (BSx) in patients with symptomatic femoropopliteal peripheral artery disease, leveraging data from the REVIVE (Revascularization Strategies in Patients With Peripheral Arterial Disease Involving the Femoropopliteal Arteries) study. Methods: The REVIVE study pooled individual patient data from 5 randomized controlled trials comparing EVT with stent implantation versus BSx. The primary end point was major adverse limb events, a composite of all‐cause death, major amputation, or reintervention. Secondary end points included amputation‐free survival, the individual components of major adverse limb events, and primary patency at 2 years. Early complications were defined as a composite of any bleeding, infection, or all‐cause death within 30 days. Results: Of 639 patients, 185 (29.0%) were women. At 2 years, there were no significant differences in major adverse limb events between EVT and BSx in women (40.6% versus 42.1%; adjusted hazard ratio [aHR], 0.93 [95% CI, 0.57–1.52]) and men (39.7% versus 34.4%; aHR, 0.98 [95% CI, 0.69–1.39]; P ‐interaction=0.963). Similarly, there were no differences in secondary end points between EVT and BSx, regardless of sex. EVT, compared with BSx, was associated with lower rates of early complications (8.7% versus 25.9%, P =0.002 in women and 5.9% versus 21.5%, P P ‐interaction =0.77) and shorter hospital stay (3.7±5.7 versus 7.2±4.3 days, P P <0.001 in men). Conclusions: Our analysis supports the efficacy and safety of EVT with stent implantation as an alternative to BSx in patients with symptomatic peripheral artery disease involving the femoropopliteal segment, regardless of sex.

  • Impact of remnant cholesterol on cardiovascular outcomes in non-myocardial infarction patients undergoing percutaneous coronary intervention

    by Nicholas Pitaro, Benjamin Bay, Samantha Sartori, Birgit Vogel, Mauro Gitto, Kenneth F Smith, Yihan Feng, Francesca Maria Di Muro, Angelo Oliva, Johny Nicolas, et al.

    Aims: Remnant cholesterol (RC), as the cholesterol content of remnant lipoproteins, has been associated with cardiovascular outcomes. However, studies investigating the impact of RC in stable patients undergoing percutaneous coronary intervention (PCI) are scarce. The present study aimed to evaluate the impact of RC on outcomes in patients undergoing PCI for a non-myocardial infarction (MI). Methods and results: Patients undergoing PCI from 2012 to 2023 at a tertiary centre were analysed. Subgroups according to calculated RC percentiles [<50th (reference), 50th to <75th, 75th to <90th, ≥ 90th] were created. The primary outcome of interest was a composite major adverse cardiovascular event (MACE) endpoint, including all-cause mortality, spontaneous myocardial infarction and stroke 1 year after PCI. Overall, 19 289 patients were included in the current analysis. Patients in higher RC percentiles were younger, less often white, had a higher BMI, and had more comorbidities. Rates for the composite MACE endpoint did not differ significantly according to RC concentrations. However, a significantly increased risk for incident MI in the highest RC percentile subgroup (≥90th percentile—adjusted hazard ratio: 1.54, 95% confidence interval: 1.07–2.22; trend P-value = 0.010) in comparison to the <50th percentile was noted. Conclusion: While RC did not associate with the composite MACE endpoint, higher concentrations of this subtype of triglyceride-rich lipoproteins were a marker for incident ischaemic endpoints such as MI in patients undergoing PCI for a non-MI.


  • Association of neutrophil-to-lymphocyte ratio with clinical outcomes after percutaneous coronary intervention

    by Angelo Oliva, Birgit Vogel, Samantha Sartori, Davide Cao, Kenneth F Smith, Benjamin Bay, Joseph Sweeny, Francesca M Di Muro, Mary Danias, Pedro Moreno, et al.

    Aims: Inflammation contributes significantly to coronary artery disease (CAD). The neutrophil-to-lymphocyte ratio (NLR) has emerged as a readily available biomarker reflecting both inflammatory and immune cells’ activity, potentially enhancing risk stratification of patients with CAD. This study evaluates the clinical impact of baseline NLR in patients undergoing percutaneous coronary intervention (PCI) for both chronic coronary syndrome and acute coronary syndrome (ACS). Methods and results: We conducted a retrospective analysis of patients undergoing PCI at Mount Sinai Hospital between 2012 and 2022. Patients were stratified into NLR quartiles and outcomes were analysed using Cox regression models. The primary endpoint was major adverse cardiovascular events (MACEs) at 1-year follow-up, including all-cause death, myocardial infarction (MI), and stroke. A total of 7287 patients were included in the study. Age, male sex, comorbidities, high-sensitivity C-reactive protein, and complexity of PCI tended to be higher in the highest NLR quartiles. At 1 year, MACE incidence increased across NLR quartiles, from 5.1% (1st quartile) to 9.3% (4th quartile) (P for trend = 0.004). Compared with the 1st quartile, the 4th NLR quartile (NLR > 5.0) was associated with increased adjusted risks of MACE [adjusted hazard ratio (adjHR) 1.52, 95% CI 1.12–2.05], all-cause death (adjHR 1.71, 95% CI 1.10–2.65), MI (adjHR 1.53, 95% CI 1.00–2.35), and bleeding (adjHR 2.01, 95% CI 1.50–2.70). Ischaemic risk associated with high NLR was more pronounced in patients presenting with ACS and chronic kidney disease (CKD). Conclusion: Baseline NLR is associated with adverse cardiovascular outcomes in CAD patients undergoing PCI. Assessment of NLR could enhance risk stratification particularly in patients with ACS and CKD.


  • Top Cited Papers

    Residual cholesterol and inflammatory risk in statin-treated patients undergoing percutaneous coronary intervention

    by Benjamin Bay, Richard Tanner, Michael Gao, Angelo Oliva, Samantha Sartori, Birgit Vogel, Mauro Gitto, Kenneth F Smith, Francesca Maria Di Muro, Amit Hooda, et al.

    Background and Aims: Elevated LDL-cholesterol levels and inflammation, as assessed by high-sensitivity C-reactive protein, correlate with cardiovascular risk. However, data on the relative impact of residual LDL-cholesterol and inflammatory risk among statin-treated patients undergoing percutaneous coronary intervention (PCI) is lacking. Hence, this study aimed to investigate the impact of residual cholesterol/inflammatory risk in patients on statin therapy undergoing PCI. Methods: From 2012 to 2022, patients at a tertiary centre undergoing PCI were analysed. Patients were stratified according to LDL-cholesterol (≥70 vs <70 mg/dL) and high-sensitivity C-reactive protein (≥2 vs 10 mg/L were excluded. The primary endpoint was major adverse cardiovascular events (MACEs), defined as the composite of all-cause mortality, spontaneous myocardial infarction, and stroke 1 year after the index PCI. Results: A total of 15 494 patients were included. After 1-year follow-up, individuals with isolated residual inflammatory risk had the highest MACE rate (5.1%), followed by patients with combined cholesterol and inflammatory risk, no residual risk, and isolated residual cholesterol risk. After multivariable Cox regression analysis, patients with residual inflammatory risk had a 1.8-fold higher risk for MACE (adjusted hazard ratio: 1.78, 95% confidence interval 1.36–2.33, P < .001) compared with those with no residual cholesterol or inflammatory risk. This was similar in patients with combined residual cholesterol and inflammatory risk (adjusted hazard ratio: 1.56, 95% confidence interval 1.19–2.04, P = 0.001). Of note, no independent association of isolated residual cholesterol risk (adjusted hazard ratio: 1.01, 95% confidence interval .76–1.35, P-value = .920) with MACE was noted (P-trend across all groups <.001). Conclusions: Among statin-treated patients undergoing PCI, residual inflammation but not cholesterol risk was associated with an increased risk of MACE during follow-up.


  • Prognostic impact of residual inflammatory and triglyceride risk in statin-treated patients with well-controlled LDL cholesterol and atherosclerotic cardiovascular disease

    by Francesca Maria Di Muro, Birgit Vogel, Samantha Sartori, Benjamin Bay, Angelo Oliva, Yihan Feng, Prakash Krishnan, Joseph Sweeny, Mauro Gitto, Kenneth Smith, et al.

    Aims: Identifying alternative contributors to the residual risk of atherosclerotic cardiovascular disease (ASCVD) beyond LDL cholesterol (LDL-C) levels is crucial. We investigated the relative impact of triglycerides (TGs) and high-sensitivity C-reactive protein (hs-CRP) on outcomes in statin-treated patients with well-controlled LDL-C undergoing percutaneous coronary intervention (PCI) for established ASCVD. Methods and results: We included 9446 statin-treated patients with LDL-C < 70 mg/dL undergoing PCI between 2012 and 2022, stratified into four groups: (i) no residual risk (TG <150 mg/dL + hs-CRP <2 mg/L); (ii) residual TG risk (TG ≥150 mg/dL + hs-CRP <2 mg/L); (iii) residual inflammatory risk (TG <150 mg/dL + hs-CRP ≥2 mg/L); and (iv) residual TG and inflammatory risk (TG ≥150 mg/dL + hs-CRP ≥2 mg/L). The primary endpoint was major adverse cardiovascular events (MACE) at 1 year, consisting of all-cause mortality, myocardial infarction, or stroke. Cox regression analysis was performed, using the no residual risk group as a reference. Of the total population, 5339 (56.5%) had no residual risk, 555 (5.9%) presented residual TG risk, 3009 (31.9%) had residual inflammatory risk, and 543 (5.7%) exhibited residual combined risk. After multivariable adjustment, patients with residual inflammatory or combined risk showed a significantly higher hazard of MACE, mainly driven by all-cause mortality. No significant difference was observed between patients with residual TG risk and those with no residual risk. Conclusion: In statin-treated patients with well-controlled LDL-C undergoing PCI, residual inflammatory risk—alone or in combination with residual TG risk—was associated with a higher incidence of MACE, highlighting the need for targeted preventive strategies beyond LDL-C lowering.


  • Validation of a high bleeding risk definition in cancer patients undergoing percutaneous coronary intervention

    by Mauro Gitto, Sean Gilhooley, Kenneth Smith, Birgit Vogel, Samantha Sartori, Benjamin Bay, Prakash Krishnan, Joseph Sweeny, Angelo Oliva, Pedro Moreno, et al.

    Aims: Due to the absence of validated bleeding risk tools in cancer patients undergoing percutaneous coronary intervention (PCI), we aimed to validate an adapted version of the Academic Research Consortium (ARC) High Bleeding Risk (HBR) criteria. Methods and results: Consecutive patients with active or remission cancer undergoing PCI between 2012 and 2022 at Mount Sinai Hospital (New York, USA) were included. Patients were considered at HBR if they met at least one of the major ARC-HBR criteria, other than cancer, or two minor criteria. The primary endpoint was a composite of periprocedural in-hospital or post-discharge bleeding at 1 year. The key secondary endpoint was major adverse cardiac and cerebrovascular events (MACCEs), including death, myocardial infarction, or stroke. Of the 2007 cancer patients included in this study, 1142 (56.9%) were classified as HBR. Moderate to severe anaemia was the most prevalent major HBR criterion (35%). At 1 year, the incidence of bleeding was significantly higher in HBR compared with non-HBR patients [10.9 vs. 3.9%, adjusted hazard ratio (HR): 2.36, 95% confidence interval (CI): 1.57–3.53, P < 0.001], mainly driven by higher periprocedural bleeding. Similarly, HBR patients were at higher risk of MACCE (11.0% vs. 3.2%, adjusted HR: 2.78, 95% CI: 1.72–4.47, P < 0.001) and death (8.8% vs. 2.2%, adjusted HR: 3.28, 95% CI: 1.87–5.77, P < 0.001) than non-HBR patients. Conclusion: An adapted version of the ARC-HBR criteria, in which cancer is not a major criterion, effectively delineates cancer patients undergoing PCI who are at HBR. Cancer patients at HBR according to this definition also exhibited a higher mortality risk.


  • Open Access

    Pharmacology in Structural Intervention for Valvular Heart Disease: Current Practice and Future Perspectives

    by Francesca Maria Di Muro, Birgit Vogel, Angelo Oliva, Benjamin Bay, Mauro Gitto, George D. Dangas, Roxana Mehran


  • Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischaemic events after percutaneous coronary intervention: a sub-study of the TWILIGHT trial

    by Usman Baber, Davide Cao, Timothy Collier, Samantha Sartori, George Dangas, Dominick J Angiolillo, Birgit Vogel, Vijay Kunadian, Carlo Briguori, David J Cohen, et al.

    Aims: In standard time-to-first event analysis, early aspirin discontinuation followed by ticagrelor monotherapy has been shown to reduce bleeding without increasing ischaemic complications compared with ticagrelor plus aspirin after percutaneous coronary intervention (PCI). We evaluated whether these treatment effects are preserved when recurrent events are considered. Methods and results: In this TWILIGHT trial post-hoc analysis, we assessed the effects of ticagrelor monotherapy on the total number of events that occurred over the 12-month follow-up among 7119 high-risk patients randomized to aspirin or placebo in addition to ticagrelor at 3 months post-PCI if event-free and adherent to treatment. There were 391 patients with at least one Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding (primary endpoint). Of those, 28 (7.2%) had a recurrent event. The total number of BARC 2, 3, or 5 bleeding events was 148 in the ticagrelor monotherapy arm compared with 278 with ticagrelor plus aspirin arm (P < 0.001). Among 272 patients with at least one key secondary ischaemic endpoint (all-cause death, myocardial infarction, or stroke), 37 (13.6%) sustained a recurrent event. Total ischaemic events were similar (155 vs. 159) in the two groups. Conclusion: Among selected high-risk patients who underwent PCI and completed 3 months of dual antiplatelet therapy followed by ticagrelor with or without aspirin, recurrent bleeding was less common than recurrent ischaemic events over 12 months. Analysis of total events indicates that ticagrelor monotherapy continues to be more effective than ticagrelor plus aspirin in reducing bleeding without a signal of ischaemic harm.